Insights

Our experience drives our insights, boostering trustworthy relationships with our clients.

Publications & MoreAll Publications

Publication

The EU HTA process should be considered a learning system

Interview in Market Access & Health Policy 01/2024

Publication

Lost in PICO?

A simulation of the EU HTA scoping process

Publication

How fast will the EU HTA child grow?

Estimation of the number of procedures of the first years of implementation

Publication

Orphan vs. Non-Orphan Drugs in Germany

Is there really a need for adjustment in the benefit assessment?

Blog articlesAll Blog articles

Blog

The Medical Research Act

Confidential reimbursement amounts in Germany only attractive for individual cases

Blog

The Medical Research Act

Exemption from AMNOG pricing guardrails if relevant proportion of clinical trials are conducted in Germany

Blog

National strategy for gene and cell therapies (GCT) handed over

Starting signal for a solution-orientated concept for Germany

Blog

Market Access Agenda in Europe

Video interview on EU HTA

EventsAll Events

Event

Ask the experts

16th of July 2024

Dr. rer. nat. Ingo Hantke

EU HTA market access strategy panel

Event

Health.Tech

5th to 6th of June 2024

Prof. Matthias P. Schönermark, M.D., Ph.D.

Innovation & business for better healthcare

Event

World Orphan Drug Congress USA 2024

23rd to 25th of Apr 2024

Prof. Matthias P. Schönermark, M.D., Ph.D.

The World’s Most Important Orphan Drug and Rare Disease Event

Event

Advanced Therapies Congress 2024

19th to 20th of Mar 2024

PD Dr. rer. nat. Sabrina Schlie-Wolter

Advancing cell and gene therapies

to the top